Faruqi & Faruqi, LLP announced on March 22 that it is reminding investors in REGENXBIO Inc. about the upcoming deadline to seek lead plaintiff status in a federal securities class action lawsuit against the company. The law firm said the deadline for this action is April 14, 2026.
The reminder is important for investors who purchased or acquired REGENXBIO securities between February 9, 2022 and January 27, 2026. These individuals may have legal rights and are encouraged to contact Faruqi & Faruqi partner James (Josh) Wilson directly to discuss their options.
“If you purchased or acquired securities in REGENXBIO between February 9, 2022 and January 27, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310),” the firm said in its statement.
Faruqi & Faruqi describes itself as a leading national securities law firm investigating potential claims against REGENXBIO Inc., which trades under the NASDAQ symbol RGNX. The case involves allegations related to investor losses during the specified period.
PR Newswire, which distributed this announcement, operates in more than 170 countries and supports press release distribution in over 40 languages according to its official website. PR Newswire aims to deliver global reach through its network of newsrooms and influencers as detailed on its official website. The service features expert editors with over a decade of experience providing around-the-clock support and SEO guidance according to the official website. PR Newswire collaborates with more than 500,000 media outlets and influencers globally according to its official website. Its services include press release distribution, AI-enhanced content tools, and social sharing features as outlined on its official website.
